Send us Fan Mail

We dig into why single-target drugs fall short against Alzheimer’s and how explainable AI can design smarter, safer combination therapies that target upstream biology while managing risks like ARIA. We share tools, data sources, and a roadmap to validate predictions with digital twins and organoids.

• global burden and rising projections
• modest gains from new antibodies and unmet need
• failed and ongoing combo trials since 2015
• PK versus PD strategies and examples
• shift to endophenotypes and network medicine
• three design patterns for combinations
• copathologies, CAA, and managing ARIA
• AI toolkits: networks, knowledge graphs, QSP
• validation via real-world data and organoids
• roadblocks in data quality, regulation, and explainability

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.

Never miss an episode—subscribe on your favorite podcast app!